Group 1: Company Overview - Chengquan Capital recently conducted research on Xiangyu Medical, revealing a projected net profit of 102.94 million yuan for 2024, a decrease of 54.68% year-on-year [1] - For Q1 2025, Xiangyu Medical's net profit is expected to be 22.95 million yuan, reflecting a year-on-year decrease of 41.26% [1] - Xiangyu Medical focuses on the "big rehabilitation" sector, emphasizing the development of rehabilitation robots and brain-machine interface products [1] Group 2: Product Development and Market Position - The portable exoskeleton assistive robot has entered the small batch production phase, with expectations to obtain medical device registration and launch sales within the year [1] - The rehabilitation industry is experiencing a continuous increase in product variety and significant improvements in technology, establishing it as a rapidly growing sector with strong market demand [1] - Xiangyu Medical's transcranial magnetic therapy robot addresses challenges such as target localization and treatment accuracy [1] Group 3: Technological Advantages - The company possesses advantages in brain-machine interface technology, including proprietary core algorithms and self-developed data collection devices [1] - In the short term, the exoskeleton robot will primarily serve medical applications, while in the medium to long term, the company plans to develop home-use versions [1] - The rehabilitation exoskeleton robot enables high-intensity, high-repetition rehabilitation training, providing objective assessment data and reducing reliance on advanced therapists [1] Group 4: Future Innovations - Xiangyu Medical is developing products that combine brain-machine interfaces with exoskeleton robots for rehabilitation training of patients with weakened lower limb strength [1]

河南翔宇医疗设备股份有限公司 2024 年年度股东大会会议资料 证券代码：688626 证券简称：翔宇医疗 河南翔宇医疗设备股份有限公司 2024 年年度股东大会 会议资料 2025 年 5 月 1 河南翔宇医疗设备股份有限公司 2024 年年度股东大会会议资料 河南翔宇医疗设备股份有限公司 2024 年年度股东大会会议资料目录 | 2024 | 年年度股东大会会议须知 | 3 | | | | --- | --- | --- | --- | --- | | 2024 | 年年度股东大会会议议程 | 6 | | | | 2024 | 年年度股东大会会议议案 | 8 | | | | 议案 | 1：关于公司 2024 | 年度董事会工作报告的议案 | | 8 | | 议案 | 2：关于公司 2024 | 年度监事会工作报告的议案 | | 16 | | 议案 | 3：关于公司 2024 | 年年度报告及其摘要的议案 | | 21 | | 议案 | 4：关于公司 2024 | 年度财务决算报告的议案 | | 22 | | 议案 | 5：关于公司 2024 | 年年度利润分配方案的议案 | | 26 | | 议案 | 6 ...

Investment Rating - Investment rating: Buy (maintained) [2][8] Core Views - The company is facing short-term pressure on performance in 2024, but is increasing R&D investment to build long-term advantages [2][6] - The company reported a revenue of 744 million yuan in 2024, a slight decrease of 0.17% year-on-year, and a net profit attributable to shareholders of 103 million yuan, down 54.68% year-on-year [6][9] - The company is focusing on the rehabilitation sector, which has significant long-term potential, while experiencing short-term profit pressure due to rising expense ratios [6][9] Financial Performance Summary - 2024 revenue: 744 million yuan (yoy -0.17%); net profit: 103 million yuan (yoy -54.68%); non-recurring net profit: 89.97 million yuan (yoy -55.90%) [6][11] - Q4 2024 revenue: 237 million yuan (yoy +16.74%); net profit: 29.53 million yuan (yoy -38.45%); non-recurring net profit: 25.54 million yuan (yoy -35.06%) [6][11] - Q1 2025 revenue: 186 million yuan (yoy +10.02%); net profit: 22.95 million yuan (yoy -41.26%); non-recurring net profit: 18.71 million yuan (yoy -48.72%) [6][11] Expense and Profitability Metrics - Sales expense ratio: 28.91% (yoy +6.10pct); management expense ratio: 8.10% (yoy +2.60pct); R&D expense ratio: 20.45% (yoy +6.12pct) [6][9] - Gross margin: 67.42%, down 1.20 pct year-on-year; net margin: 13.83%, down 16.82 pct year-on-year [6][9] R&D Investment and Future Outlook - R&D investment in 2024 was 152 million yuan, an increase of 42.41% year-on-year, accounting for 20.45% of total revenue [6][9] - The company has established multiple R&D centers and is focusing on advanced technologies such as brain-machine interfaces and rehabilitation robotics [7][9] - Revenue projections for 2025-2027 are 848 million yuan, 972 million yuan, and 1.121 billion yuan, with growth rates of 14.1%, 14.6%, and 15.3% respectively [8][11] Earnings Per Share and Valuation - Expected EPS for 2025-2027: 0.94 yuan, 1.21 yuan, and 1.57 yuan, with corresponding P/E ratios of 38x, 29x, and 23x [9][11]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2][8] Core Views - The company's performance is under short-term pressure in 2024, but increased R&D investment is expected to build long-term advantages [2][6] - The company reported a revenue of 744 million yuan in 2024, a year-on-year decrease of 0.17%, and a net profit attributable to shareholders of 103 million yuan, down 54.68% year-on-year [6][9] - The company is focusing on the rehabilitation sector, which has significant long-term potential despite short-term profit pressures due to rising expense ratios [6][9] Financial Performance Summary - In 2024, the company achieved a revenue of 744 million yuan, with a year-on-year change of -0.17% [6][11] - The net profit attributable to shareholders was 103 million yuan, reflecting a year-on-year decline of 54.68% [6][11] - The company’s gross margin was 67.42%, down 1.20 percentage points year-on-year, and the net margin was 13.83%, down 16.82 percentage points year-on-year [6][11] - R&D expenses increased by 42.41% year-on-year to 152 million yuan, representing 20.45% of total revenue [6][11] Revenue Breakdown - Revenue from rehabilitation therapy equipment was 504 million yuan, up 9.85% year-on-year [6][9] - Revenue from rehabilitation training equipment was 165 million yuan, down 19.89% year-on-year [6][9] - Revenue from rehabilitation assessment equipment was 27.62 million yuan, down 21.92% year-on-year [6][9] Future Projections - Revenue projections for 2025, 2026, and 2027 are 848 million yuan, 972 million yuan, and 1.121 billion yuan, respectively, with growth rates of 14.1%, 14.6%, and 15.3% [8][11] - Net profit projections for the same years are 151 million yuan, 194 million yuan, and 251 million yuan, with growth rates of 46.5%, 28.8%, and 29.3% [8][11] - The expected EPS for 2025, 2026, and 2027 are 0.94 yuan, 1.21 yuan, and 1.57 yuan, respectively [8][11]

Group 1 - The core products of Zhaoli Pharmaceutical show stable growth, with a high dividend payout ratio maintained, achieving a revenue of 2.578 billion yuan in 2024, a year-on-year increase of 32.71% [8][9] - The company has significantly reduced costs and improved efficiency, with a notable decrease in expense ratios, including a sales expense ratio of 32.53%, down 7.5 percentage points year-on-year [9] - The company plans to implement an employee stock ownership plan by the end of 2024, with profit growth targets set at no less than 30% for 2025 [10] Group 2 - Weining Health's revenue for Q1 2025 was 345 million yuan, a year-on-year decrease of 30.24%, with a net profit of 5.29 million yuan, down 68.18% [11][12] - The company is focusing on cost reduction and efficiency improvement, with a significant increase in cash flow from operating activities, up 120.53% year-on-year [12] - The WiNEX product is entering a phase of mass delivery, supporting internet operations and international adaptation, with a strong digital architecture capable of handling millions of transactions [14][15] Group 3 - Lais Information's revenue for 2024 was 1.61 billion yuan, a year-on-year decrease of 3.94%, while Q1 2025 revenue dropped by 55.53% to 109 million yuan [17][18] - The company is optimizing its business structure, with significant growth in air traffic control and urban traffic management sectors, achieving revenue increases of 13.68% and 33.47% respectively [18][19] - The company is enhancing its research and development efforts, with a focus on refining its product offerings and improving operational efficiency [20] Group 4 - FenJung Media reported a revenue of 12.262 billion yuan in 2024, a year-on-year increase of 3.01%, with a net profit of 5.155 billion yuan, up 6.80% [23][25] - The company maintains a high dividend payout ratio, with cash dividends amounting to 4.766 billion yuan, representing 92.45% of net profit [24][25] - The planned acquisition of New潮传媒 is expected to enhance the company's competitive position in the outdoor advertising market [28] Group 5 - Jingwang Electronics achieved a revenue of 12.659 billion yuan in 2024, a year-on-year increase of 17.68%, with a net profit of 1.169 billion yuan, up 24.86% [30][31] - The company is expanding its production capacity, with a focus on high-end markets and AI applications, particularly in the automotive sector [32][33] - The company is increasing its R&D investments to support technological advancements and market expansion [33]

Group 1 - The A-share brain-computer interface sector experienced an initial rise, with Aipeng Medical increasing by over 8% [1] - Chengyitong, Rongtai Health, and Xiangyu Medical all saw increases of over 5% [1] - Companies such as Dineike and Sanbo Neuroscience also followed the upward trend [1]

Core Insights - The exoskeleton robots are gaining popularity in various scenic spots in China, such as Huangshan, Taishan, and Wugong Mountain, attracting tourists' interest [1] - The technology integrates artificial intelligence, sensing, ergonomics, power, and electronics, indicating a significant market potential across multiple sectors including medical rehabilitation, military, industrial, and transportation [1][2] Application Areas - Exoskeleton robots can assist users in walking and lifting heavy objects, with a reported ability to help lift 30 kilograms with ease [1] - These devices weigh around 2 kilograms and enhance the wearer's leg or waist strength, reducing physical exertion and absorbing impact to lessen stress on knees and ankles [1] - The market for rehabilitation exoskeletons is projected to reach 48 billion yuan by 2030, while the industrial sector could see a market space of over 10 billion yuan [2] Commercialization Progress - Several A-share listed companies, including Jiangsu Zhenjiang New Energy Equipment Co., Ltd., Henan Xiangyu Medical Equipment Co., Ltd., and Zhejiang Jinggong Integrated Technology Co., Ltd., are actively involved in the exoskeleton robot industry chain [2] - Zhenjiang's subsidiary, Haipuman Robotics, is focused on intelligent control algorithms and plans to begin small-scale production of exoskeleton robots by Q3 2025 [3] - Xiangyu Medical is advancing its portable exoskeleton walking robot towards market launch, aiming to obtain medical device registration within the year [3] - Jinggong Technology is testing its hip exoskeleton robot for various scenarios, including stair climbing and running [3] Industry Challenges - Key challenges in the exoskeleton robot industry include improving battery life, reducing device weight, enhancing comfort, optimizing control algorithms, and lowering costs, which are crucial for widespread application and commercialization [3]

Group 1 - The company Henan Xiangyu Medical Equipment Co., Ltd. has developed a transcranial magnetic-assisted therapy robot that has recently received national medical device registration, allowing it to assist in the treatment of related diseases [1] - The company is accelerating the research and development of key technologies such as embodied intelligent robots and multimodal integration, aiming to create a new highland for innovation and integrated application in the rehabilitation industry [1] - The rehabilitation science city project in Neihuang County is under construction, covering an area of 286 acres and including a high-end traditional Chinese medicine rehabilitation equipment industrial park [1] Group 2 - The Henan Guangyuan New Materials Electronic Materials Industrial Park project has officially commenced production, marking a shift towards high-grade electronic materials for artificial intelligence and high-frequency servers [2] - The project was completed in just over a year, demonstrating effective project management and execution [2] - The local government has implemented measures to stimulate economic growth, including a series of consumption promotion activities and investment expansion initiatives [3]

Investment Rating - The report assigns a "Buy" rating for Xiangyu Medical (688626) as it initiates coverage [1][7]. Core Insights - Xiangyu Medical is focusing on the development of brain-machine interfaces and rehabilitation robots, with revenue stabilizing and poised for growth [1]. - The company reported a slight decline in revenue for 2024 but showed signs of recovery in the last two quarters, with a 10% increase in Q1 2025 [4][6]. - Significant investment in R&D, with a 42% increase in 2024, indicates a commitment to maintaining technological leadership in the rehabilitation industry [6][7]. Financial Performance Summary - In 2024, the company achieved operating revenue of 744 million yuan, a decrease of 0.17% year-on-year, and a net profit of 103 million yuan, down 55% [4][6]. - For Q1 2025, revenue was 186 million yuan, reflecting a 10% increase, while net profit was 23 million yuan, a decrease of 41% [4][6]. - Revenue projections for 2025-2027 are 846 million yuan, 982 million yuan, and 1.141 billion yuan, with expected growth rates of 14%, 16%, and 16% respectively [6][8]. Profitability and Valuation Metrics - The forecasted net profits for 2025-2027 are 156 million yuan, 199 million yuan, and 255 million yuan, with growth rates of 52%, 27%, and 28% respectively [7][8]. - The projected P/E ratios for the same period are 39, 31, and 24 [7][8]. - The company maintains a strong gross margin, with 67.83% in 2024, although it is expected to slightly decline in the following years [6][9].

2024 年度持续督导工作现场检查报告 上海证券交易所： 国泰海通证券股份有限公司（以下简称"国泰海通"、"保荐人"）作为河南 翔宇医疗设备股份有限公司（以下简称"翔宇医疗"或"公司"）首次公开发行 股票并在科创板上市的保荐人，根据《中华人民共和国公司法》《中华人民共和 国证券法》《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市 规则》（以下简称"《上市规则》"）和《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等有关法律法规的规定，对公司 2024 年度（以下简称"本 持续督导期间"）的规范运作情况进行了现场检查，现就现场检查的有关情况报 告如下： 一、本次现场检查的基本情况 （一）保荐人 国泰海通证券股份有限公司 国泰海通证券股份有限公司 关于河南翔宇医疗设备股份有限公司 1 （二）保荐代表人 刘君、岑平一 （三）现场检查时间 2025 年 4 月 14 日至 2025 年 4 月 17 日 （四）现场检查人员 刘君、李景玉 （五）现场检查内容 现场检查人员对本持续督导期内发行人公司治理及内部控制、信息披露、独 立性、与关联方的资金往来、募集资金使用情况、关联交易、对外担保、重 ...